Carbamazepine (Epilepsy)

Neonatal disorders (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15365
R63210		 Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 Neonatal complications during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.82 [0.28;2.40] C
excluded (control group) 		5/27   23/106 28 27
ref
S15366
R63223		 Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 Neonatal complications during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 0.98 [0.32;3.02] C 5/27   15/80 20 27
ref
S6685
R18606		 D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 Neonatal conditions throughout pregnancy prospective cohort unexposed, disease free excluded Adjustment: No Matched 4.67 [0.37;59.40] C
excluded (control group) 		1/3   6/62 7 3
ref
S6689
R18723		 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 Neonatal conditions throughout pregnancy prospective cohort unexposed, sick Adjustment: No 1.50 [0.08;26.86] C 1/3   2/8 3 3
ref
Total 2 studies 1.04 [0.37;2.96] 23 30
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023Bromley, 2023 1 0.98[0.32; 3.02]202787%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: low D'Souza (Carbamazepine) (Controls unexposed, sick), 1991D'Souza, 1991 2 1.50[0.08; 26.86]3313%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.04[0.37; 2.96]23300.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.04[0.37; 2.96]23300%NABromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.04[0.37; 2.96]23300%NABromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 2 Tags Adjustment   - No  - No 1.04[0.37; 2.96]23300%NABromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 2 All studiesAll studies 1.04[0.37; 2.96]23300%NABromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 6685, 15365

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 4.67[0.37; 59.40]73 -NAD'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 1 unexposed, sick controlsunexposed, sick controls 1.04[0.37; 2.96]23300%NABromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.82[0.28; 2.40]2827 -NABromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 10.510.01.0